Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
about
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapyAurora kinases in head and neck cancerMolecular changes in the multistage pathogenesis of head and neck cancerEvidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity.Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckRationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapyCetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data.Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.Understanding resistance to EGFR inhibitors-impact on future treatment strategiesCetuximab in the treatment of head and neck cancer: preliminary results outside clinical trialsPhase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.Cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.Emerging drugs to treat squamous cell carcinomas of the head and neck.A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat modelManagement of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research programNew approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).The Chinese medicine JC-001 enhances the chemosensitivity of Lewis lung tumors to cisplatin by modulating the immune responseCurrent status of cetuximab for the treatment of patients with solid tumors.Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition.Head and neck cancer: past, present and future.The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.Cetuximab in squamous cell carcinoma of the head and neck.Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
P2860
Q21198850-4F96C8B9-E227-4D41-A377-FA1D4F298F47Q26750719-21CDE8A0-21D3-49DB-B45B-E0B758E6BC26Q26765429-60C0AC49-0028-460C-B725-185F0FF29781Q28476652-5DD2453D-1C5C-4D6E-9BBF-E23C5876E742Q28654389-BB8F93BE-40DE-422E-8329-A11486B2956DQ28728638-B7708EE7-2D97-4EB8-BC9E-32CD558F7F08Q30498197-E9035D6D-F4AF-44B0-A65F-816DF88A7C33Q33378256-49A2369B-DC66-479F-B041-B0EFB6C8AE27Q33387432-2F212085-EEB9-44FA-AFAF-326892E6A697Q33570512-26182792-E912-4FEF-95A8-515A699DAC68Q33650470-65FD73A2-022B-441F-96A9-8678791C27EEQ33839177-0047781F-CA30-48A6-AB58-80772439BB9FQ33873118-0F684A89-2F38-413B-96DF-ED3D41E6C690Q33916035-188B5D28-9A4F-471C-9E6A-C60DAC05ABD0Q33941497-47A738F6-1B44-4267-90FA-C2716B5061CFQ34088424-FB5D8ECA-7E93-4035-9CF2-67D4B439AC13Q34417953-FCEC07D1-8DE5-4FA6-98AA-1169D9FC1784Q34570074-E9D4A533-8996-4EAE-AF13-15856EE74AD4Q34618994-15C35B50-3492-4D7C-8E01-613FAC243B44Q34999913-8E319EA8-DBD0-45D7-BDB6-94BE42D099C7Q35001415-4E4DB09A-6C89-4534-A6F9-388042B0D008Q35091386-EA65EF0A-1DB5-482C-A163-A21C38038A3AQ35098322-797D123A-064F-4F3A-977D-0BC862CA39FCQ35238022-1AF0D73E-2481-425A-8FE3-FC337B3968FAQ35439353-637A1500-8BBF-490D-878B-1B25D4D0F220Q35584416-F8CDD519-757B-4F7C-A1C5-7B345010036DQ35913241-EE595F30-F446-496C-B7D9-1602836681ADQ36055127-7472A668-AB46-4132-920F-4CBE2F1ED5DBQ36072292-A10CBCB4-C729-4C0E-AAE1-8DF72550673DQ36117881-59C4E739-1527-4269-B0DC-04A1169F5E20Q36303845-59BE28A7-168E-4578-B72F-9C21B0E4EABBQ36343870-A18CBADD-A450-403C-A599-0F0D4AF0EA5FQ36364973-5225F063-493F-47A7-AEE3-45E70F32FC18Q36371601-0006F437-079F-4236-A978-812488CDB163Q36480951-1A403E06-865A-468A-9BFA-3201CE0BEFBBQ36503161-E0FDBEE9-85CA-4742-B488-6E34B0D99B34Q36532126-EB752F3A-6DE5-4F1B-95C7-2F27B75137D2Q36545328-D49BEB68-F9EC-4946-AC9A-D15F31300710Q36572511-9D47EF90-F515-4E60-AC03-5BECC8D7BFEFQ36613969-1F77F527-3012-472C-807A-C97CDB2F8484
P2860
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Phase II multicenter study of ...... arcinoma of the head and neck.
@en
Phase II multicenter study of ...... arcinoma of the head and neck.
@nl
type
label
Phase II multicenter study of ...... arcinoma of the head and neck.
@en
Phase II multicenter study of ...... arcinoma of the head and neck.
@nl
prefLabel
Phase II multicenter study of ...... arcinoma of the head and neck.
@en
Phase II multicenter study of ...... arcinoma of the head and neck.
@nl
P2093
P356
P1476
Phase II multicenter study of ...... arcinoma of the head and neck.
@en
P2093
Dong M Shin
Karel Dicke
Matthew Arquette
Merrill S Kies
Nozar Azarnia
Waun Ki Hong
P304
P356
10.1200/JCO.2005.07.120
P407
P577
2005-07-11T00:00:00Z